Loracarbef: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Secondary bacterial infection of acute bronchitis

Adult: 200-400 mg 12 hrly for 7 days.

Oral
Skin and soft tissue infections

Adult: 200 mg 12 hrly for 7 days.
Child: 6 mth-12 yr: 7.5 mg/kg 12 hrly for 7 days.

Oral
Uncomplicated urinary tract infections

Adult: 200 mg daily for 7 days.

Oral
Acute bacterial exacerbation of chronic bronchitis

Adult: 400 mg 12 hrly for 7 days.

Oral
Acute otitis media

Child: 6 mth-12 yr as oral suspension: 15 mg/kg 12 hrly for 10 days.

Oral
Sinusitis

Adult: 400 mg 12 hrly for 10 days.
Child: 6 mth-12 yr: 15 mg/kg 12 hrly for 10 days.

Oral
Pneumonia, Pyelonephritis

Adult: 400 mg 12 hrly for 14 days.

Oral
Pharyngitis, Tonsillitis

Adult: 200 mg 12 hrly for 10 days.
Child: 6 mth-12 yr: 7.5 mg/kg 12 hrly for 10 days.

Renal Impairment

Patients with CrCl of 10-49 mL/min: Half the usual dose at the usual dosage interval or full dose at twice the usual interval; <10 mL/min: Usual dose every 3-5 days. Patients on haemodialysis should receive another dose following dialysis.

Administration

Should be taken on an empty stomach. Take 1 hr before or at least 2 hr after meals.

Contraindications

Hypersensitivity to β-lactams.

Special Precautions

Impaired renal function, history of colitis.

Adverse Reactions

Diarrhoea, nausea, vomiting, abdominal pain; headache; skin rashes; abnormalities in haematological parameters; elevations in hepatic enzymes, hepatic dysfunction.

Pregnancy Category (US FDA)

PO: B

Drug Interactions

Plasma concentration is increased by probenecid.

Action

Description: Loracarbef is a carbacephem antibiotic. It is bactericidal through binding to essential target proteins of the bacterial cell wall, leading to inhibition of cell-wall synthesis, thus preventing cell division.
Pharmacokinetics:
Absorption: Well absorbed from GI tract. Peak plasma levels after 1.2 hr (capsule) or 40-60 min (liquid). Absorption delayed significantly by food.
Distribution: 25% bound to plasma proteins.
Excretion: Excreted in the urine as unchanged drug.

MIMS Class

Other Beta-Lactams

Disclaimer: This information is independently developed by MIMS based on Loracarbef from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com